HRGN
HARVARD APPRATS REG TCHstockOTC
biostage, inc. (otcqb: bstg) is a pioneering biotechnology company developing bioengineered organ implants to address unmet needs in the treatment of life-threatening cancer, traumas and congenital abnormalities of the esophagus, bronchus and trachea. the company's cellframe™ technology platform is engineered to stimulate the body's signaling pathways and natural healing process to regenerate and restore organ function. combining a synthetic scaffold with tissue engineering and cell biology, biostage's cellframe™ platform is used to create organ specific cellspan™ implants. the cellspan™ implant is delivered directly to the site where tissue regeneration is needed, and has been designed to promote in situ tissue regeneration by providing both stem cell-derived biological signals, and three-dimensional guidance and support for cell growth differentiation. recent large animal data delivered promising results as cellframe™-based cellspan™ implants applied to the esophagus achieved regener
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 1.98 | 2026-11-12 | -4.04% | 5.698 |
| 1M | 2.21 | 2026-10-19 | -14.18% | -1.872 |
| 3M | 1.52 | 2026-08-20 | +25.08% | -2.193 |
| 6M | 1.40 | 2026-05-19 | +35.71% | -1.351 |
| 1Y | 1.69 | 2025-11-25 | +12.43% | -0.855 |
| 2Y | 2.97 | 2024-11-20 | -36.05% | — |
| 5Y | 4.45 | 2023-07-20 | -57.30% | -0.297 |
HARVARD APPRATS REG TCH (OTC:HRGN) stock price today is $1.90, and today's volume is 2,222. HRGN is up 0.000% today. The 30 day average volume is 4,071. HRGN market cap is $27.29M with 14.37M shares outstanding.